S Haas

Summary

Publications

  1. doi request reprint Prevention of venous thromboembolism using enoxaparin in day surgery: results of the SMART noninterventional study
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Munchen, Germany
    Clin Appl Thromb Hemost 18:265-71. 2012
  2. doi request reprint Novel oral anticoagulants--key messages for the angiologist
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, TU Munchen, Munich, Germany
    Vasa 41:177-91. 2012
  3. doi request reprint Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer
    Sylvia K Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Germany
    Clin Appl Thromb Hemost 18:159-65. 2012
  4. pmc Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Germany
    BMC Cancer 11:316. 2011
  5. ncbi request reprint Identifying patient- and treatment-related factors related to amputation risk in cases of heparin-induced thrombocytopenia treated with argatroban
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung der Technischen Universität München, Munich, Germany
    Int Angiol 30:541-6. 2011
  6. ncbi request reprint [Prevention of thromboembolism in surgery]
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Klinikum rechts der Isar, Technische Universitat Munchen
    Unfallchirurg 107:1065-86; quiz 1087. 2004
  7. ncbi request reprint New anticoagulants: from bench to bedside
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Ismaninger Str 22, 81675 Munich, Germany
    Hamostaseologie 27:41-7. 2007
  8. ncbi request reprint [New anticoagulants -- their clinical significance]
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Munchen
    Ther Umsch 60:19-23. 2003
  9. doi request reprint [Thrombosis prophylaxis in surgery. What is the evidence?]
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Normannenstrasse 34a, Munich, Germany
    Chirurg 82:1085-90. 2011
  10. ncbi request reprint [Prevention of deep vein thrombosis in surgical departments]
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Klinikum rechts der Isar, Technische Universitat Munchen, Munich
    Chirurg 75:323-42; quiz 343. 2004

Detail Information

Publications18

  1. doi request reprint Prevention of venous thromboembolism using enoxaparin in day surgery: results of the SMART noninterventional study
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Munchen, Germany
    Clin Appl Thromb Hemost 18:265-71. 2012
    ..Adverse drug reactions were experienced by 3.1% of patients. The present study results demonstrate that it is effective and tolerable to use a risk stratified dose of 20 or 40 mg enoxaparin in patients undergoing day surgery...
  2. doi request reprint Novel oral anticoagulants--key messages for the angiologist
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, TU Munchen, Munich, Germany
    Vasa 41:177-91. 2012
    ..In particular, patients with comorbidities and co-medications may require individual decision making in order to prevent bleeding complications...
  3. doi request reprint Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer
    Sylvia K Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Germany
    Clin Appl Thromb Hemost 18:159-65. 2012
    ..5% vs 10.2%; P = .032) without increased bleeding. In conclusion, thrombosis risk and prophylactic benefit was highest in stage IV lung carcinoma patients...
  4. pmc Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Germany
    BMC Cancer 11:316. 2011
    ..Patients with cancer have an increased risk of VTE. We compared VTE rates and bleeding complications in 1) cancer patients receiving LMWH or UFH and 2) patients with or without cancer...
  5. ncbi request reprint Identifying patient- and treatment-related factors related to amputation risk in cases of heparin-induced thrombocytopenia treated with argatroban
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung der Technischen Universität München, Munich, Germany
    Int Angiol 30:541-6. 2011
    ..Factors that influenced patients proceeding to amputation are unclear...
  6. ncbi request reprint [Prevention of thromboembolism in surgery]
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Klinikum rechts der Isar, Technische Universitat Munchen
    Unfallchirurg 107:1065-86; quiz 1087. 2004
    ..The development of new anticoagulants is expanding the range of prophylactic methods, which means further in-formation is needed...
  7. ncbi request reprint New anticoagulants: from bench to bedside
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Ismaninger Str 22, 81675 Munich, Germany
    Hamostaseologie 27:41-7. 2007
    ....
  8. ncbi request reprint [New anticoagulants -- their clinical significance]
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Munchen
    Ther Umsch 60:19-23. 2003
    ..The results obtained from various clinical trials with these compounds are extremely encouraging. Thus, a significant improvement of antithrombotic treatment may be expected by their future use in the clinical and out-patient setting...
  9. doi request reprint [Thrombosis prophylaxis in surgery. What is the evidence?]
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Normannenstrasse 34a, Munich, Germany
    Chirurg 82:1085-90. 2011
    ....
  10. ncbi request reprint [Prevention of deep vein thrombosis in surgical departments]
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Klinikum rechts der Isar, Technische Universitat Munchen, Munich
    Chirurg 75:323-42; quiz 343. 2004
    ..The development of new anticoagulants is expanding the range of prophylactic methods, which means further information is needed...
  11. ncbi request reprint Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial)
    S Haas
    Institute for Experimental Oncology and Therapy Research, Technical University of Munich, Munich, Germany
    Int Angiol 25:335-42. 2006
    ..However, the ability of pharmacologic thromboprophylaxis to prevent major venous thromboembolism, defined as proximal deep vein thrombosis, and/or pulmonary embolism, and/or death, has not been previously validated...
  12. ncbi request reprint [Prevention of deep vein thrombosis in surgical and non-surgical patients]
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Ismaninger Str 22, 81675 Munchen
    Hamostaseologie 29:91-5. 2009
    ..Recently, also oral direct thrombin- and factor Xa-inhibitors have become available for patients undergoing hip or knee replacement surgery who always are at high risk for VTE complications...
  13. ncbi request reprint Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets
    W P Jeske
    Cardiovascular Institute and Department of Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL 60153, USA
    Thromb Res 88:271-81. 1997
    ..These results suggest that glycoprotein Ilb/IIIa inhibitors may be beneficial in the management of heparin-induced thrombocytopenia and warrant further investigation...
  14. doi request reprint [Thromboembolism prophylaxis in trauma surgery: S3 guidelines and significance of the amendment for trauma surgeons]
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675, Munchen, Deutschland
    Unfallchirurg 113:893-900. 2010
    ..The availability of these new compounds increases the spectrum of prophylaxis modalities thereby creating a need for new information in trauma surgery...
  15. doi request reprint [Dabigatran therapy--perioperative management and interpretation of coagulation tests]
    M Spannagl
    Haemostaseologie Campus Innenstadt, Klinikum der Universitat Munchen, Munchen, Germany
    Hamostaseologie 32:294-305. 2012
    ..A distinct feature of dabigatran is the possibility of effectively removing dabigatran from the circulation by haemodialysis...
  16. ncbi request reprint [Future potential indications for an oral thrombin inhibitor]
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Germany
    Hamostaseologie 22:36-43. 2002
    ..Because of the mitogenic effects of thrombin on the proliferation of tumour cells, additional experimental studies aiming at a potential inhibition of thrombin-triggered oncogenesis is of uttermost interest...
  17. ncbi request reprint Idiopathic venous thrombosis. Long-term anticoagulation therapy? Yes
    S Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Technische Universitat Munchen, Ismaninger Str 22, 81675 Munchen, Germany
    Hamostaseologie 26:48-51. 2006
    ....
  18. ncbi request reprint Factors influencing survival after resection of pulmonary metastases from colorectal cancer
    H Vogelsang
    Department of Surgery, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 Munich, Germany
    Br J Surg 91:1066-71. 2004
    ..The aim of this study was to evaluate clinically relevant prognostic factors and to define a subgroup of patients who would most benefit from such surgery...